AtaiBeckley Inc. ATAI 深 沪
等待开盘 02-11 09:30:00 美东时间
3.85
-0.085
-2.16%
华盛通- 最 高4.01
- 今 开3.90
- 成交量 427.85万股
- 最 低 3.81
- 昨 收 3.935
- 总市值 13.98亿
- 52周最高 6.75
- 市盈率 静 --
- 换手率 1.18%
- 52周最低 1.15
- 委 比 84.06%
- 总股本 3.63亿
- 历史最高 22.91
- 量 比 1.02
- 振 幅 5.08%
- 历史最低 1.025
- 每 手 1
- 风险率 1.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 存储再获大行看好！花旗、瑞银和美银齐上调西部数据、希捷科技等公司目标价；PNC金融服务获6家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Soleno Therapeutics"买入"评级，目标价从110美元升至120美元；富国银行：维持Soleno Therapeutics"超配"评级，目标价从106美元升至114美元
01-21 11:42
Guggenheim Initiates Coverage On AtaiBeckley with Buy Rating, Announces Price Target of $11
Guggenheim analyst Eddie Hickman initiates coverage on AtaiBeckley (NASDAQ:ATAI) with a Buy rating and announces Price Target of $11.
01-20 22:10
FDA Lifts Hold On GH Research's Depression Drug Trial After Two Years
The FDA lifted its clinical hold on GH Research's GH001 after Phase 2b data showed rapid, durable benefits in treatment-resistant depression, clearing the path toward Phase 3 trials planned for 2026.
01-05 22:37
美股大行评级 | 潜在涨幅63.56%！拜玛林制药获Truist Securities升目标价至100美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持拜玛林制药"买入"评级，目标价从80美元升至100美元；HC Wainwright & Co.：维持Savara"买入"评级，目标价从8美元升至10美元
2025-12-24 11:17
Jones Trading Initiates Coverage On Atai Beckley with Buy Rating, Announces Price Target of $16
Jones Trading analyst Justin Walsh initiates coverage on Atai Beckley (NASDAQ:ATAI) with a Buy rating and announces Price Target of $16.
2025-12-23 21:59
Atai Beckley Granted New Patent Covering EMP-01, Further Strengthening IP Estate And Long-Term Exclusivity For The Program
Atai Beckley N.V. (NASDAQ:ATAI) ("AtaiBeckley" or the "Company"), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health
2025-12-11 20:04
ATAI Life Sciences Q3 EPS $(0.28) Misses $(0.12) Estimate, Sales $749.000K Beat $55.560K Estimate
ATAI Life Sciences (NASDAQ:ATAI) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.12) by 133.33 percent. This is a 75 percent decrease over losses of $(0.16) per share
2025-11-12 20:14
美股大行评级 | 超配！万事达、Visa、Block获多家机构首予评级；奈飞、德州仪器遭多家机构下调目标价
今日重点评级关注：Canaccord Genuity：维持ATAI Life Sciences"买入"评级，目标价从11美元升至14美元；麦格理：维持Cleanspark"跑赢大市"评级，目标价从20美元升至30美元
2025-10-23 10:06
ATAI Life Sciences Closes $149.5 Million Public Offering
ATAI Life Sciences ( ($ATAI) ) has provided an announcement. On October 20, 202...
2025-10-21 21:58
ATAI Life Sciences’ BPL-003 Receives FDA Breakthrough Designation
ATAI Life Sciences ( ($ATAI) ) has provided an announcement. On October 16, 202...
2025-10-17 05:19
